Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase

Explore clinical trials studying Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase. Study availability and eligibility vary by location and protocol.

6 public trials 0 recruiting studies

Refine in advanced search Browse all conditions

Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase trial results

Not Yet Recruiting

EVAluation of Erythrocytosis PRospEctive Cohort STudy

NCT06785870

Conditions: Bone Marrow Diseases, Bone Marrow Neoplasms, Disease, +17 more
Locations: Victoria Hospital, London Health Sciences Centre London, Ontario, Canada

View Trial Details

Completed

Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm

NCT01787487

Conditions: Bone Marrow Diseases, Bone Marrow Neoplasms, Hematologic Diseases, +10 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Completed

LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

NCT02098161

Conditions: Bone Marrow Diseases, Bone Marrow Neoplasms, Hematologic Diseases, +9 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Completed

Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

NCT00397813

Conditions: Anemia, Anemia, Hemolytic, Anemia, Refractory, +40 more
Locations: LDS Hospital Salt Lake City, Utah, United States

Veterans Administration Center-Seattle Seattle, Washington, United States

Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Active, Not Recruiting

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT03862157

Conditions: Acute Myeloid Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blood Coagulation Disorders, +43 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, Not Recruiting

Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis

NCT04517851

Conditions: Bone Marrow Diseases, Bone Marrow Neoplasms, Hematologic Diseases, +9 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase

Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase trial results

EVAluation of Erythrocytosis PRospEctive Cohort STudy

Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm

LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis

Related conditions